Lisa Genovese
Optometrist · Amherst, NYNPI 1487659553
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Reichert, Inc. at 46.5% of the total. Reporting peaked in 2024 at $29,370 and has fallen 93.3% since, to $1,980 in 2025. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $280.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reichert, Inc.$37K
- LKC Technologies, Inc.$17K
- Sun Pharmaceutical Industries Inc.$16K
- Biotissue Holdings Inc.$2K
- Alcon$2K
- Bausch & Lomb Americas Inc.$987
- plus $5K from 18 others
What the payments were for
- Consulting fees$33,77242%
- Speaking & faculty fees$31,02139%
- Travel & lodging$6,0788%
- Food & beverage$9,28412%
- Gifts$190%
- Entertainment$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Reichert, Inc. | 15 | $37,263 |
| LKC Technologies, Inc. | 2 | $17,270 |
| Sun Pharmaceutical Industries Inc. | 40 | $16,463 |
| Biotissue Holdings Inc. | 23 | $2,057 |
| Alcon | 51 | $1,602 |
| Bausch & Lomb Americas Inc. | 27 | $987 |
| Kala Pharmaceuticals, Inc. | 25 | $759 |
| Johnson & Johnson Vision Care, Inc. | 19 | $706 |
| Sight Sciences, Inc. | 9 | $570 |
| AbbVie(2 entities) | 12 | $555 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $524 |
| Novartis | 20 | $415 |
| Oyster Point Pharma, Inc. | 9 | $298 |
| Tarsus Pharmaceuticals, Inc. | 5 | $225 |
| Glaukos Corporation | 1 | $122 |
| Coopervision Inc. | 3 | $110 |
| Dompe US, Inc. | 3 | $75 |
| Astellas Pharma US Inc | 2 | $56 |
| Optos, Inc. | 1 | $45 |
| Shire North American Group Inc | 2 | $44 |
| Alcon Research LLC | 1 | $21 |
| Harrow Eye, LLC | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Maculogix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dry Eye Demo Products$27,999
- RETEVAL$17,250
- CEQUA$15,545
- Prokera$1,756
- AmnioGraft$1,756
- EYSUVIS$506
- MIEBO$359
- INVELTYS$269
- DURYSTA$248
- XIIDRA$234
- DAILIES TOTAL1$133
- OMNI(R) SURGICAL SYSTEM (US)$132
- INFUSE$126
- iDoseTR$122
- OMNI$119
- TYRVAYA$119
- BTOD$112
- TRYPTYR$108
- BIOTRUE ONE DAY$105
- ILUX$105
How this compares
$80,220 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 19 | $25,755 |
| MieboPerfluorohexyloctane/Pf | 17 | $13,070 |
| Cyclosporine | 14 | $10,549 |
| LumiganBimatoprost | 13 | $4,295 |
| Loteprednol Etabonate | 21 | $3,280 |
| Timolol Maleate | 23 | $2,342 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $1,838 |
| Latanoprost | 153 | $1,226 |
| Brimonidine Tartrate | 18 | $386 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $987 | $38,82536 claims |
| AbbVieLumigan | $555 | $4,29513 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $524 | $3,28021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Amherst
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.